Eidos Therapeutics to Present at 31st Annual ROTH Conference
March 11 2019 - 08:00AM
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that
management is scheduled to participate in a fireside chat regarding
Eidos at the 31st Annual ROTH Conference on Monday, March 18th at
8:30 a.m. PDT in Orange County, CA.
A live audio webcast at ir.eidostx.com. An archived replay of
the webcast will be available on the company's website for 90 days
following the live presentation.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is
developing AG10, a potentially disease-modifying therapy for the
treatment of ATTR. AG10 is currently being studied in a pivotal
global phase 3 trial (ATTRibute-CM) in ATTR cardiomyopathy
patients. The innovative trial design includes two potentially
registrational endpoints, change in 6-minute walk distance at 12
months and reduction in all-cause mortality and
cardiovascular-related hospitalizations at 30 months. For more
information, please visit www.eidostx.com.
About transthyretin amyloidosis (ATTR)
ATTR represents a significant unmet medical need with a large
patient population and an inadequate current standard of care. ATTR
is caused by the destabilization of TTR due to inherited mutations
or aging and is commonly divided into three distinct categories:
wild-type ATTR cardiomyopathy (ATTRwt-CM), mutant ATTR
cardiomyopathy (ATTRm-CM), and ATTR polyneuropathy (ATTR-PN). The
worldwide prevalence of each disease is approximately 400,000
patients, 40,000 patients and 10,000 patients, respectively.
All three forms of ATTR are progressive and fatal. For patients
with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in
life (age 50+), with median survival of three to five years from
diagnosis. ATTR-PN either presents in a patient's early 30s or
later (age 50+), and results in a median life expectancy of five to
ten years from diagnosis. Progression of all forms of ATTR causes
significant morbidity, impacts productivity and quality of life,
and creates a significant economic burden due to the costs
associated with progressively greater patient needs for supportive
care.
About AG10
AG10 is an investigational, orally-administered small molecule
designed to potently stabilize tetrameric transthyretin, or TTR,
thereby halting at its outset the series of molecular events that
give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in
subjects with symptomatic ATTR-CM, AG10 was generally well
tolerated, demonstrated >90% average TTR stabilization at day
28, and increased serum TTR concentrations, a prognostic indicator
of survival in a retrospective study of ATTR-CM patients, in a
dose-dependent manner. AG10 is currently being studied in an
open-label extension of a Phase 2 clinical trial in patients with
ATTR-CM and sites are currently being activated for a Phase 3
clinical trial of AG10 in patients with ATTR-CM (ATTRibute-CM).
AG10 was designed to mimic a naturally-occurring variant of the
TTR gene (T119M) that is considered a rescue mutation because
co-inheritance has been shown to prevent ATTR in individuals also
inheriting a pathogenic, or disease-causing, mutation in the TTR
gene. To our knowledge, AG10 is the only TTR stabilizer in
development that has been observed to mimic the stabilizing
structure of this rescue mutation.
Media Contact:
Carolyn Hawley, Canale Communications, (619) 849-5382,
carolyn@canalecomm.com
Investor Contact:
Alex Gray, Burns McClellan, (212) 213-0006,
agray@burnsmc.com
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Mar 2023 to Mar 2024